154 related articles for article (PubMed ID: 32266805)
1. Incidence trends for epithelial peritoneal, ovarian, and fallopian tube cancer during 1999-2016: a retrospective study based on the Korean National Cancer Incidence Database.
Shin W; Won YJ; Yoo CW; Lim J; Lim MC
J Gynecol Oncol; 2020 Jul; 31(4):e56. PubMed ID: 32266805
[TBL] [Abstract][Full Text] [Related]
2. Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
Weiss AS; Swisher E; Pennington KP; Radke M; Khasnavis N; Garcia RL; Kilgore MR; Lee MK; Norquist BM
Gynecol Oncol; 2020 Oct; 159(1):214-220. PubMed ID: 32709535
[TBL] [Abstract][Full Text] [Related]
3. Second Primary Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers after Breast Cancer Diagnosis: Korea Central Cancer Registry.
Ha HI; Lee EG; Lim J; Jung SY; Chang YJ; Won YJ; Lim MC
Cancer Res Treat; 2021 Apr; 53(2):541-548. PubMed ID: 33211942
[TBL] [Abstract][Full Text] [Related]
4. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
Dahm-Kähler P; Borgfeldt C; Holmberg E; Staf C; Falconer H; Bjurberg M; Kjölhede P; Rosenberg P; Stålberg K; Högberg T; Åvall-Lundqvist E
Gynecol Oncol; 2017 Jan; 144(1):167-173. PubMed ID: 27817932
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.
Cortesi L; De Matteis E; Toss A; Marchi I; Medici V; Contu G; Xholli A; Grandi G; Cagnacci A; Federico M
Oncology; 2017; 93(6):377-386. PubMed ID: 28848147
[TBL] [Abstract][Full Text] [Related]
6. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
7. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.
Liao CI; Chow S; Chen LM; Kapp DS; Mann A; Chan JK
Gynecol Oncol; 2018 May; 149(2):318-323. PubMed ID: 29514737
[TBL] [Abstract][Full Text] [Related]
8. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
Levine DA; Argenta PA; Yee CJ; Marshall DS; Olvera N; Bogomolniy F; Rahaman JA; Robson ME; Offit K; Barakat RR; Soslow RA; Boyd J
J Clin Oncol; 2003 Nov; 21(22):4222-7. PubMed ID: 14615451
[TBL] [Abstract][Full Text] [Related]
9. Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study.
Lim MC; Won YJ; Lim J; Salehi T; Yoo CW; Bristow RE
BMC Cancer; 2018 Aug; 18(1):800. PubMed ID: 30089478
[TBL] [Abstract][Full Text] [Related]
10. Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer.
Tanner EJ; Long KC; Feffer JB; Leitao MM; Abu-Rustum NR; Barakat RR; Chi DS; Gardner GJ
Gynecol Oncol; 2013 Jan; 128(1):28-33. PubMed ID: 23017819
[TBL] [Abstract][Full Text] [Related]
11. High-grade serous ovarian and fallopian tube carcinomas with similar clinicopathological characteristics might originate from serous tubal intraepithelial carcinoma in Chinese women.
Wang J; Wu H; Zhang Y; Zhang Y; Li X; Zhao Q; Meng F; Huang Q; Wang Y
Int J Clin Exp Pathol; 2017; 10(8):8222-8232. PubMed ID: 31966673
[TBL] [Abstract][Full Text] [Related]
12. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Shih KK; Chi DS; Barakat RR; Leitao MM
Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
Martin JY; Urban RR; Liao JB; Goff BA
J Gynecol Oncol; 2016 Sep; 27(5):e47. PubMed ID: 27329195
[TBL] [Abstract][Full Text] [Related]
14. Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis.
Somasegar S; Reddy RA; Chow S; Dorigo O; Renz M; Karam A
Gynecol Oncol; 2024 May; 184():190-197. PubMed ID: 38330833
[TBL] [Abstract][Full Text] [Related]
15. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series.
Shih KK; Chi DS; Barakat RR; Leitao MM
Gynecol Oncol; 2010 May; 117(2):330-5. PubMed ID: 20189234
[TBL] [Abstract][Full Text] [Related]
16. Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960-2014: A population-based cohort study.
Leandersson P; Hogberg T; Dickman PW; Malander S; Borgfeldt C
BMC Cancer; 2021 Apr; 21(1):465. PubMed ID: 33902507
[TBL] [Abstract][Full Text] [Related]
17. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.
Rosenthal AN; Fraser L; Manchanda R; Badman P; Philpott S; Mozersky J; Hadwin R; Cafferty FH; Benjamin E; Singh N; Evans DG; Eccles DM; Skates SJ; Mackay J; Menon U; Jacobs IJ
J Clin Oncol; 2013 Jan; 31(1):49-57. PubMed ID: 23213100
[TBL] [Abstract][Full Text] [Related]
18. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
[TBL] [Abstract][Full Text] [Related]
19. Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology--a prospective comparative study.
Schnack TH; Sørensen RD; Nedergaard L; Høgdall C
Gynecol Oncol; 2014 Nov; 135(2):278-84. PubMed ID: 25168689
[TBL] [Abstract][Full Text] [Related]
20. Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Cheng M; Lee HH; Chang WH; Lee NR; Huang HY; Chen YJ; Horng HC; Lee WL; Wang PH
Int J Environ Res Public Health; 2019 Nov; 16(23):. PubMed ID: 31795359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
